← signals
2026-08-11·MSFT·revenue concentration risk
lowdown

Microsoft's SEC XBRL fundamentals (10-K filed 2026-07-29) show FY revenue of $245.1B and net income of $88.1B.

Microsoft's SEC XBRL fundamentals (10-K filed 2026-07-29) show FY revenue of $245.1B and net income of $88.1B.

window 30devidence 41confidence score 100price MSFT $506.06

confidence score

Strong evidence: 7 independent source classes support this read.

100
low confidence7 independent source classesofficialnewscommunityothermarketpasses publish gate
priced-in check

MSFT has not made a large direction-matching 30-90 day move yet.

not priced in
as of 2026-08-107d n/a45d n/a90d +24%yahoo

signal brief

Microsoft's SEC XBRL fundamentals (10-K filed 2026-07-29) show FY revenue of $245.1B and net income of $88.1B. A more AI-infra-specific signal comes from Windows Central coverage aggregated on Hacker News: Microsoft filings suggest roughly 70% of Microsoft's AI revenue is concentrated entirely on OpenAI. This is a material concentration risk: a majority of MSFT's AI monetization depends on one partner that designs its own models and could plausibly change compute sourcing or renegotiate terms. The bull case is that the number validates strong Azure/OpenAI revenue and sustained GPU demand. The bear case is that any disruption to the relationship — renegotiation, OpenAI building its own capacity, or regulatory scrutiny — would directly hit a large share of MSFT's AI revenue. Given the emphasis on concentration, the bear case is more material for forward risk assessment. Confidence is low because the claim comes from secondary coverage rather than an explicit line item in the filing, but it is actionable for monitoring hyperscaler AI economics and OpenAI's infrastructure footprint.

What the sources said

  • HN / Windows Central: "Microsoft filings suggest 'around 70%' of its AI revenue is concentrated entirely on OpenAI."
  • SEC XBRL: "revenue: 245122000000 (10-K filed 2026-07-29)" and "net_income: 88136000000."

source data used

Decision support, not stock advice. This signal is research with cited evidence — not a recommendation to buy, sell, or hold any security.